Skip to content
HowShorted

Aquestive Therapeutics, Inc. short interest in 2021

In 2021, Aquestive Therapeutics, Inc.'s disclosed short interest ran from 5.81% of shares outstanding on 15 Jan 2021 to 3.42% on 31 Dec 2021, a change of -2.39 percentage points. The year's high was 9.14% on 14 May 2021 and its low 2.84% on 15 Nov 2021, averaging 5.44% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 7.64 days on 28 May 2021. Full history: Aquestive Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Aquestive Therapeutics, Inc. in 2021

2021 in figures

Start of year
5.81% (15 Jan 2021)
End of year
3.42% (31 Dec 2021)
Change
-2.39 pp
High
9.14% (14 May 2021)
Low
2.84% (15 Nov 2021)
Average
5.44%
Highest days to cover
7.64 (28 May 2021)
SEC filings marked
8

Every report in 2021

Aquestive Therapeutics, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 20215.81%2.47
29 Jan 20214.08%1.79
12 Feb 20213.71%1.14
26 Feb 20217.81%3.09
15 Mar 20216.76%2.4510-K filed, results (8-K)
31 Mar 20217.81%4.34
15 Apr 20217.19%3.82
30 Apr 20218.13%6.04
14 May 20219.14%5.4510-Q filed, results (8-K)
28 May 20218.38%7.64
15 Jun 20218.23%5.10
30 Jun 20216.66%2.61
15 Jul 20216.19%5.30
30 Jul 20215.16%5.00
13 Aug 20215.25%3.3010-Q filed, results (8-K)
31 Aug 20214.04%3.05
15 Sep 20213.70%3.20
30 Sep 20213.67%3.92
15 Oct 20213.11%4.27
29 Oct 20213.68%2.08
15 Nov 20212.84%1.7010-Q filed, results (8-K)
30 Nov 20212.98%2.06
15 Dec 20212.86%1.73
31 Dec 20213.42%1.00

See also: Aquestive Therapeutics, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.